1. Design and synthesis of aryloxypropanolamine as β3-adrenergic receptor antagonist in cancer and lipolysis
- Author
-
Chunxiao Miao, Xiongwen Zhang, Zhilong Wang, Wanli Zhang, Xin Xie, Jin Jiyu, and Wei Lu
- Subjects
0301 basic medicine ,Pharmacology ,Chemistry ,Organic Chemistry ,Antagonist ,Adipose tissue ,Cancer ,General Medicine ,medicine.disease ,Cachexia ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Weight loss ,030220 oncology & carcinogenesis ,Drug Discovery ,medicine ,Lipolysis ,medicine.symptom ,Receptor ,Thermogenesis - Abstract
β-adrenergic receptors (β-ARs) are broadly distributed in various tissues and regulate a panel of important physiological functions and disease states including cancer. Above all, β3-adrenergic receptor (β3-AR) plays a significant role in regulating lipolysis and thermogenesis in adipose tissue. In this study, we designed and synthesized a series of novel L-748,337 derivatives as selective human β3-AR antagonists. Among all the tested L-748,337 analogs, compound 23d was found to display 23-fold more potent β3-AR antagonist activity (EC50 = 0.5117 nM) than L-748,337 (EC50 = 11.91 nM). In vivo, compound 23d could alleviate weight loss and inhibit tumor growth in C26 tumor cachexia animal model.
- Published
- 2018